Neuroengineering with engineered endosymbionts

Neuroengineering with engineered endosymbionts

Christopher H. Contag and Ahmed A. Zarea from Michigan State University’s Institute for Quantitative Health Science and Engineering explore therapeutic approaches to neurodegenerative diseases using a novel strategy based on engineered endosymbionts systems that could revolutionize patient care. Neurodegenerative diseases are characterized by the progressive loss of neurons and their function; in the case of Parkinson’s disease (PD), dopaminergic neurons are lost. This leads to significant deficits in motor control and cognitive function. Neuronal degeneration in PD primarily affects neurons in the substantia nigra, a brain region crucial for regulating movement. Current therapies, including the drug Levodopa and deep brain stimulation, primarily alleviate symptoms rather than address the underlying causes of neuronal death. (1)